We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A superior heterologous prime‐boost vaccination strategy against COVID‐19: A bivalent vaccine based on yeast‐derived RBD proteins followed by a heterologous vaccine.
- Authors
Liu, Yu; Li, Miao; Cui, Tingting; Chen, Zhian; Xu, Liangting; Li, Wenjuan; Peng, Qinhua; Li, Xingxing; Zhao, Danhua; Valencia, C. Alexander; Dong, Biao; Wang, Zhongfang; Chow, Hoi Yee; Li, Yuhua
- Abstract
Various vaccines have been challenged by SARS‐CoV‐2 variants. Here, we reported a yeast‐derived recombinant bivalent vaccine (Bivalent wild‐type [Wt]+De) based on the wt and Delta receptor‐binding domain (RBD). Yeast derived RBD proteins based on the wt and Delta mutant were used as the prime vaccine. It was found that, in the presence of aluminium hydroxide (Alum) and unmethylated CpG‐oligodeoxynucleotides (CpG) adjuvants, more cross‐protective immunity against SARS‐CoV‐2 prototype and variants were elicited by bivalent vaccine than monovalent wtRBD or Delta RBD. Furthermore, a heterologous boosting strategy consisting of two doses of bivalent vaccines followed by one dose adenovirus vectored vaccine exhibited cross‐neutralization capacity and specific T cell responses against Delta and Omicron (BA.1 and BA.4/5) variants in mice, superior to a homologous vaccination strategy. This study suggested that heterologous prime‐boost vaccination with yeast‐derived bivalent protein vaccine could be a potential approach to address the challenge of emerging variants.
- Subjects
COVID-19 vaccines; VACCINATION; SARS-CoV-2; ALUMINUM hydroxide; VACCINES
- Publication
Journal of Medical Virology, 2024, Vol 96, Issue 3, p1
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.29454